Moreover, Gene Expression Omnibus (GEO) database analysis revealed that MRPL12 expression was upregulated in tumors of sorafenib non‐responsive HCC patients (Figure 4J), suggesting the potential of MRPL12 as a biomarker to predict the efficacy of sorafenib in HCC patients. This evidence concerns the gene MRPL12 and hepatocellular carcinoma.